Literature DB >> 14991330

Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register.

V Neumann1, A Rütten, M Scharmach, K-M Müller, M Fischer.   

Abstract

Between 1987 and 2000, the German mesothelioma register recorded a total of 4,455 patients with malignant mesotheliomas. Survival times for 498 (11.2%) patients were available; 155 patients (study group, 3.5% of the total group) survived for more than 2 years and 343 patients (control group, 7.7% of the total group) survived for fewer than 24 months. Male patients were over-represented in both groups, with 13% of women in the study and 4.4% in the control group. The proportion of pleural mesotheliomas was more than 90% in both groups, with peritoneal cases comprising 6.5% in the study group and 3.2% in the control group. Histologically, the epithelioid subtype was represented in 58% of the study group, whereas the biphasic subtype predominated (67.6%) in the control group. Only 7% of tumours were of the sarcomatoid subtype. The average age of patients in the study group was 57.4 years, thus lower than in the control group (62.8 years). Lung dust analysis showed an increased pulmonary asbestos burden in 94% of all patients; significant differences between the study and control group were not observed. In the majority of the total group pleural effusions were the first symptoms. Therapeutic data were available in fewer than 40% of all cases. Surgical interventions were performed, partly in combination with radiation and chemotherapy and as alternative treatments. Significant deviations in survival time dependent on therapy applied could not be proved. By multivariate analysis (Cox proportional hazards regression model) favourable prognostic factors for long-term survival were epithelioid tumour subtype, comparatively young age (<60 years), and female gender ( P<0.05).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991330     DOI: 10.1007/s00420-003-0498-6

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  53 in total

Review 1.  Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.

Authors:  Paul Baas
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

2.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

3.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

4.  Prognostic value of FDG PET imaging in malignant pleural mesothelioma.

Authors:  F Bénard; D Sterman; R J Smith; L R Kaiser; S M Albelda; A Alavi
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

5.  The clinical aspects of mesothelioma.

Authors:  P C Elmes; J C Simpson
Journal:  Q J Med       Date:  1976-07

6.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

Authors:  D H Sterman; J Treat; L A Litzky; K M Amin; L Coonrod; K Molnar-Kimber; A Recio; L Knox; J M Wilson; S M Albelda; L R Kaiser
Journal:  Hum Gene Ther       Date:  1998-05-01       Impact factor: 5.695

7.  Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites.

Authors:  K Browne; W J Smither
Journal:  Br J Ind Med       Date:  1983-05

8.  Malignant peritoneal mesothelioma: review of 25 patients.

Authors:  J Brenner; P P Sordillo; G B Magill; R B Golbey
Journal:  Am J Gastroenterol       Date:  1981-04       Impact factor: 10.864

Review 9.  [Pleural mesothelioma: etiology and practical consequences].

Authors:  H J Woitowitz; K Grossgarten
Journal:  Pneumologie       Date:  1991-04

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  13 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].

Authors:  M Ried; U Speth; T Potzger; R Neu; C Diez; M Klinkhammer-Schalke; H-S Hofmann
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

4.  Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma.

Authors:  Terence C Chua; Peng Yao; Javed Akther; Lawrence Young; Shisan Bao; Ushma Samaraweera; Tristan D Yan; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-04-29       Impact factor: 3.201

5.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.

Authors:  D T Arnold; C E Hooper; A Morley; P White; I D Lyburn; J Searle; M Darby; T Hall; D Hall; N M Rahman; E De Winton; A Clive; V Masani; A Dangoor; S Guglani; P Jankowska; S A Lowndes; J E Harvey; J P Braybrooke; N A Maskell
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

7.  Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.

Authors:  Tomomi Hirata; Qingfeng Zheng; Zhao Chen; Hiroyasu Kinoshita; Junichi Okamoto; Johannes Kratz; Hui Li; Natalie Lui; Hanh Do; Tiffany Cheng; Hsin-Hui Katty Tseng; Kiyoshi Koizumi; Kazuo Shimizu; Hai-Meng Zhou; David Jablons; Biao He
Journal:  Oncol Rep       Date:  2015-01-29       Impact factor: 3.906

8.  Gender Differences in Outcomes of Patients With Mesothelioma.

Authors:  Naomi Alpert; Maaike van Gerwen; Raja Flores; Emanuela Taioli
Journal:  Am J Clin Oncol       Date:  2020-11       Impact factor: 2.787

9.  Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.

Authors:  Harvey I Pass; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

Review 10.  Clinical staging of malignant pleural mesothelioma: current perspectives.

Authors:  Maria Bonomi; Costantino De Filippis; Egesta Lopci; Letizia Gianoncelli; Giovanna Rizzardi; Eleonora Cerchiaro; Luigi Bortolotti; Alessandro Zanello; Giovanni Luca Ceresoli
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.